TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05416463

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Intra-Operative Device for THA
Description: The intervention group will receive primary elective THA with the use of Intellijoint HIP 3D mini-optical navigation tool.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Intra-Operative Device for THA
Description: The intervention group will receive primary elective THA with the use of Intellijoint HIP 3D mini-optical navigation tool.
Study: NCT05550220

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Cuff Leak Test
Description: Cuff leak test is a simple and convenient tool that can be used to predict upper-airway obstruction after extubation. The CLT is used to assess airway patency through listening for an air leak and observing changes in tidal volume (VT) after the cuff is deflated.

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Cuff Leak Test
Description: Cuff leak test is a simple and convenient tool that can be used to predict upper-airway obstruction after extubation. The CLT is used to assess airway patency through listening for an air leak and observing changes in tidal volume (VT) after the cuff is deflated.
Study: NCT06412042

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Probiotic BLa80
Description: Collect baby fecal samples, test for 16S rRNA, and analyze changes in the gut microbiota before and after supplementation.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Maltodextrin
Description: Collect baby fecal samples, test for 16S rRNA, and analyze changes in the gut microbiota before and after supplementation.
Study: NCT05120934

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amitriptyline 25 MG
Description: 25 mg orally for 4 weeks
Study: NCT04598321

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Talazoparib Oral Capsule
Description: An orally available PARP inhibitor for the treatment of advanced breast cancer with germline BRCA mutations.
Study: NCT05082935

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Phase II Promotores de Salud
Description: Community partners (e.g., Mexican Consulate) select events for testing and use their usual outreach methods to attract participants to the site and their event. Then, at the community partner's event, the research team holds COVID-19 testing events and the Promotores de Salud health behavior intervention is delivered by bilingual research staff. The health behavior intervention includes: 1) psychoeducation to promote hand-washing, social distancing, mask wearing if unvaccinated, and continued testing to mitigate the spread of COVID-19 and psychoeducation to address vaccine hesitancy; 2) information support and service navigation to address logistical challenges associated with testing and vaccination (e.g., scheduling health care visits, transportation, language barriers); 3) motivational interviewing to explore personal, social, and behavioral barriers to testing and vaccination, and to discuss available resources.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Phase I Promotores de Salud Outreach
Description: Testing events re-occur every two weeks at the same location and time, based on census density on Latinx individuals for site selection. Outreach conducted by promotores occurs to increase attendance at the testing events. Outreach is culturally responsive (e.g., culturally tailored radio announcements, social media posts, community canvassing, referral by community leaders).
Study: NCT06554041

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dental Crown with Titanium-Abutment
Description: Participants in this clinical trial will receive dental implants and single screw-retained crowns made from one of four different materials: titanium, PEEK (Polyetheretherketone), zirconia, or lithium disilicate (e.max). The implants will be placed in the posterior region of the mandible or maxillae. The study will evaluate the impact of these materials on peri-implant soft tissue health by measuring inflammatory markers in the peri-implant crevicular fluid and assessing clinical outcomes such as bleeding on probing and pocket depth at 3 and 6 months post-implantation.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dental Crown with PEEK (Polyetheretherketone)-Abutment
Description: Participants in this clinical trial will receive dental implants and single screw-retained crowns made from one of four different materials: titanium, PEEK (Polyetheretherketone), zirconia, or lithium disilicate (e.max). The implants will be placed in the posterior region of the mandible or maxillae. The study will evaluate the impact of these materials on peri-implant soft tissue health by measuring inflammatory markers in the peri-implant crevicular fluid and assessing clinical outcomes such as bleeding on probing and pocket depth at 3 and 6 months post-implantation.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dental Crown with Zirconia-Abutment
Description: Participants in this clinical trial will receive dental implants and single screw-retained crowns made from one of four different materials: titanium, PEEK (Polyetheretherketone), zirconia, or lithium disilicate (e.max). The implants will be placed in the posterior region of the mandible or maxillae. The study will evaluate the impact of these materials on peri-implant soft tissue health by measuring inflammatory markers in the peri-implant crevicular fluid and assessing clinical outcomes such as bleeding on probing and pocket depth at 3 and 6 months post-implantation.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dental Crown with Lithium-Disilicate-Abutment (e.max)
Description: Participants in this clinical trial will receive dental implants and single screw-retained crowns made from one of four different materials: titanium, PEEK (Polyetheretherketone), zirconia, or lithium disilicate (e.max). The implants will be placed in the posterior region of the mandible or maxillae. The study will evaluate the impact of these materials on peri-implant soft tissue health by measuring inflammatory markers in the peri-implant crevicular fluid and assessing clinical outcomes such as bleeding on probing and pocket depth at 3 and 6 months post-implantation.
Study: NCT04925765

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Virtual Reality Biofeedback Session
Description: The Flowly intervention treatment utilizes virtual reality and biofeedback to train patients to auto-regulate themselves and improve their pain/anxiety/depression.
Study: NCT05120934

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amitriptyline 25 MG
Description: 25 mg orally for 4 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amitriptyline 50 MG
Description: 50 mg orally for 4 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Duloxetine 30 MG
Description: 30mg orally for 4 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Duloxetine 30 MG
Description: 30mg orally for 4 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Duloxetine 60 MG
Description: 60mg orally for 4 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo 30 MG
Description: 30mg tablet with no active study ingredient for 4 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo 30 MG
Description: 30mg tablet with no active study ingredient for 4 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo 30 MG
Description: 30mg tablet with no active study ingredient for 4 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo 60 MG
Description: 60mg tablet with no active study ingredient for 4 weeks
Study: NCT04673617

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AB-101
Description: NK cell therapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AB-101
Description: NK cell therapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Anti-CD20 antibody therapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Anti-CD20 antibody therapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Interleukin-2
Description: Immune cytokine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Interleukin-2
Description: Immune cytokine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Lymphodepleting chemotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Lymphodepleting chemotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Lymphodepleting chemotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Lymphodepleting chemotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bendamustine
Description: Chemoimmunotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bendamustine
Description: Chemoimmunotherapy
Study: NCT06244940

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Whole Genome Sequencing (WGC) from subject samples
Description: Perform whole genome sequencing (WGS) on fetuses with prenatally detected congenital heart disease (CHD) who meet inclusion criteria. Assess diagnostic yield of WGS in CHD and effect of prenatal versus postnatal phenotype on diagnostic yield.
Study: NCT04920812

Intervention type: GENETIC
Intervention: diagnosis of mitochondrial myopathy
Description: • Determination of the presence of specific molecular signatures at the RNA level in muscles and fibroblasts from patients
Study: NCT05303753

Intervention type: OTHER
Group type: OTHER
Intervention: fermented dairy protein with prebiotic fiber
Description: During the intervention period, the participant will consume a new product and will reduce the amount of protein in their normal diet reflecting the protein content of the new product.
Study: NCT04862819

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: new local drug delivery
Description: In the first group, on one side of the dental arch, the drug under evaluation will be used, and on the other side srp

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: scaling root planing
Description: In the second group, on one side of the dental arch srp will be performed

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: scaling root planing
Description: In the second group, on one side of the dental arch srp will be performed
Study: NCT05630508

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: interactive Mhealth Lifestyle behavior intervention
Description: Receiving Standard care, LIVEN educational material and interactive LIVEN application, via having a human component which is a health coach for 3 months
Study: NCT05031247

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Wellbeing Program
Description: The community navigator program was developed during a three-phase community-based participatory research project that aims to examine emotional/mental health needs and address access to mental health services among immigrants and refugees from Muslim-majority countries.
Study: NCT06139055

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSBR-1290 (Capsule/Tablet)
Description: Participants will receive GSBR-1290 oral capsules or tablets.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSBR-1290 (Capsule/Tablet)
Description: Participants will receive GSBR-1290 oral capsules or tablets.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSBR-1290 (Capsule/Tablet)
Description: Participants will receive GSBR-1290 oral capsules or tablets.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSBR-1290
Description: Participants will receive GSBR-1290 oral tablets.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSBR-1290
Description: Participants will receive GSBR-1290 oral tablets.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Participants will receive matching-placebo oral tablets.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Participants will receive matching-placebo oral tablets.
Study: NCT05630508

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham
Description: Receiving standard care, LIVEN educational material and access to the application
Study: NCT06139055

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo (Capsule/Tablet)
Description: Participants will receive matching-placebo oral capsules or tablets.
Study: NCT05578053

Intervention type: DRUG
Intervention: Dalpiciclib
Description: a new, orally administered, selective CDK4/6 inhibitor
Study: NCT05571072

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Opioid calculator
Description: Our research group previously created an Opioid calculator that can be used to predict the number of opioids needed post-operatively based on patient health history and characteristics.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard opioid prescription
Description: Patients will receive prescription for post-operative opioids based on what the attending surgeon usually provides.
Study: NCT06073769

Intervention type: DRUG
Intervention: Oral azacitidine
Description: Maintenance therapy according to the approved label
Study: NCT06312618

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Description: After completion of the procedure and after regain muscle power sevoflurane administration will be ceased. children will be randomized to receive propofol~1mg/kg over 10 minutes (group 1) .

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine
Description: After completion of the procedure and after regain muscle power sevoflurane administration will be ceased. children will be randomized to receive dexmedetomidine 0.2 mcg/kg over 10 minutes (group 2).
Study: NCT05023161

Intervention type: BIOLOGICAL
Intervention: Blood samples
Description: Performed a 10 ml blood sample in each of the 200 patients included.
Study: NCT05558969

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: pregnant women taking magnesium
Description: The patient group who received magnesium as a 4-6 g loading and 2-3 g/h maintenance dose to prevent convulsions in preeclampsia. Pregnant will be operated under general anesthesia. Sugammadex 4mg/kg will be administered when TOF 0 response is seen at the end of surgery. The time from TOF 0 to TOF 0.9 will be recorded. Magnesium and calcium levels in the blood will be studied.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Pregnant women who do not receive magnesium therapy and who will be operated under general anesthesia. Sugammadex 4mg/kg will be administered when TOF 0 response is seen at the end of surgery. The time from TOF 0 to TOF 0.9 will be recorded. Magnesium and calcium levels in the blood will be studied.
Study: NCT06218979

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Risperidone oral solution
Description: See arm/group descriptions

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Risperidone oral solution
Description: See arm/group descriptions

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Risperidone oral solution
Description: See arm/group descriptions
Study: NCT04963777

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Prebiotic
Description: Chicory root derived inulin-type fructan (13.2 kcal/day for ages 8-13 years; 26.4 kcal/day for ages ≥14 years)

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Maltodextrin (isocaloric; 13.2 kcal/day for ages 8-13 years; 26.4 kcal/day for ≥14 years)
Study: NCT04802161

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo collection of blood samples

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Biospecimen Collection
Description: Undergo collection of blood samples

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Marrow Aspiration and Biopsy
Description: Undergo bone marrow aspirate and biopsy

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Bone Marrow Aspiration and Biopsy
Description: Undergo bone marrow aspirate and biopsy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liposome-encapsulated Daunorubicin-Cytarabine
Description: Given IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Liposome-encapsulated Daunorubicin-Cytarabine
Description: Given IV
Study: NCT05344911

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propofol combined with alfentanil
Description: Anesthesia induction: midazolam 0.02 mg/kg, propofol（TCI） 3 μ g/mL, alfentanil 20 μ g/kg and rocuronium 0.6 mg/kg . Anesthesia maintenance: target-controlled infusion of propofol combined with alfentanil(0.5-2ug/kg/min)
Study: NCT04802161

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pomalidomide
Description: Given PO
Study: NCT06082453

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Quantitative polymerase chain reaction (qPCR) assay for detection of Treponema pallidum
Description: A quantitative polymerase chain reaction (qPCR) assay detects and quantifies DNA in a sample, and the qPCR assay used in this study targets the polA gene of T. pallidum to confirm presence of T. pallidum in a sample. Samples will be collected from the mother/newborn dyad at the time of birth. qPCR data will only be used to determine testing performance and will not be used in clinical management of study participants.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Aptima Treponema pallidum transcription-mediated amplification (TMA) assay for detection of Treponema pallidum
Description: The Aptima transcription-mediated amplification (TMA) assay used in this study will target RNA of T. pallidum to confirm presence of T. pallidum in a sample. Samples will be collected from the mother/newborn dyad at the time of birth. TMA data will only be used to determine testing performance and will not be used in clinical management of study participants.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Center for Disease Control (CDC) Sexually Transmitted Infections (STI) 2021 Treatment Guidelines for diagnosis of syphilis
Description: Using the Center for Disease Control (CDC) Sexually Transmitted Infections (STI) 2021 Treatment Guidelines, new born syphilis infection is categorized by clinical providers at birth as follows: confirmed proven/highly probably, possible congenital syphilis (CS), CS less likely, or CS unlikely. These CS categories are determined using neonatal nontreponemal test results, physical exam of the infant, placental pathology, and maternal serologies and treatment history, and comparison of maternal and neonatal nontreponemal tiers. These data will be collected as part of standard clinical care.
Study: NCT04570956

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tamoxifen
Description: Oral Tamoxifen 10 mg/day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topical 4-OHT( 4-hydroxytamoxifen)gel 4 mg/each breast/day
Description: Topical 4-OHT (4-hydroxytamoxifen) gel 4 mg/each breast/day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: placebo pill or placebo gel

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study: NCT06561347

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zanubrutinib
Description: A potent, specific, and irreversible Bruton tyrosine kinase (BTK) inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bendamustine
Description: Alkylating agent

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Monoclonal antibody
Study: NCT06003985

Intervention type: OTHER
Intervention: Gastric Ultrasound Exam
Description: A gastric ultrasound is a simple, fast, non-invasive bedside diagnostic test that provides a qualitative and quantitative assessment of gastric contents. There are no known risks of a gastric ultrasound exam.

Intervention type: OTHER
Intervention: Gastric Ultrasound Exam
Description: A gastric ultrasound is a simple, fast, non-invasive bedside diagnostic test that provides a qualitative and quantitative assessment of gastric contents. There are no known risks of a gastric ultrasound exam.
Study: NCT05262569

Intervention type: OTHER
Intervention: ileus
Description: retrospectively allocation according to a postoperative outcome-ileus
Study: NCT06371014

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ondansetron oral membrane
Description: A new oral film formulation of ondansetron was used to replace traditional tablets in the treatment of antiemetic chemotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ondansetron oral membrane
Description: A new oral film formulation of ondansetron was used to replace traditional tablets in the treatment of antiemetic chemotherapy
Study: NCT06483763

Intervention type: OTHER
Group type: OTHER
Intervention: SmokerFace App from the Education Against Tobacco (EAT) program
Description: The SmokerFace App utilizes photo-aging technology that requires users to take a selfie. This selfie is processed by the software to generate four images depicting the consequences of smoking (or not smoking) one pack a day over both a one-year and 15 years. The app provides explanations of these smoking beauty-reducing visual outcomes and educates users about the aesthetic impacts of smoking, along with potential health consequences.
Study: NCT05221892

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gamma-aminobutyric acid tartarate, glutamic acid, dibasic calcium phosphate, thiamine nitrate, pyridoxine chloride and cyanocobalamin
Description: Tablets to be taken 30 minutes before each of 4 trips.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ginger
Description: Tablets to be taken 30 minutes before each of 4 trips.
Study: NCT06398873

Intervention type: DRUG
Intervention: Dupilumab 300 MG/2 ML Subcutaneous Solution [DUPIXENT]
Description: 300mg/2 weeks
Study: NCT06483763

Intervention type: OTHER
Group type: OTHER
Intervention: The use of standardized school-based educational module
Description: This module is designed to promote a tobacco- and nicotine-free environment and is validated by at least three experts in related fields (27). The intervention will be customized to fit the Omani sociocultural context and will be administered in the classrooms of respective schools by the same team of trained medical students
Study: NCT04511026

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lymphoseek
Description: Radioactive diagnostic agent

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Single Photon Emission Computed Tomography (SPECT)
Description: Imaging test